Acadian Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.08M | Buy |
92,600
+68,589
| +286% | +$3.76M | 0.01% | 581 |
|
|
2025
Q1 | $1.7M | Sell |
24,011
-6,889
| -22% | -$486K | ﹤0.01% | 801 |
|
|
2024
Q4 | $2.03M | Buy |
30,900
+18,170
| +143% | +$1.19M | 0.01% | 761 |
|
|
2024
Q3 | $892K | Buy |
12,730
+617
| +5% | +$43.2K | ﹤0.01% | 939 |
|
|
2024
Q2 | $994K | Buy |
12,113
+9,576
| +377% | +$786K | ﹤0.01% | 992 |
|
|
2024
Q1 | $221K | Buy |
2,537
+625
| +33% | +$54.4K | ﹤0.01% | 1169 |
|
|
2023
Q4 | $184K | Sell |
1,912
-1,770
| -48% | -$170K | ﹤0.01% | 1247 |
|
|
2023
Q3 | $325K | Buy |
3,682
+1,660
| +82% | +$147K | ﹤0.01% | 1104 |
|
|
2023
Q2 | $175K | Buy |
+2,022
| New | +$175K | ﹤0.01% | 1298 |
|
|
2022
Q3 | – | Sell |
-12,060
| Closed | -$1M | – | 1677 |
|
|
2022
Q2 | $1M | Buy |
12,060
+11,629
| +2,698% | +$964K | 0.01% | 817 |
|
|
2022
Q1 | $32K | Buy |
431
+344
| +395% | +$25.5K | ﹤0.01% | 1514 |
|
|
2021
Q4 | $7K | Sell |
87
-321,579
| -100% | -$25.9M | ﹤0.01% | 1642 |
|
|
2021
Q3 | $24.8M | Buy |
321,666
+285,148
| +781% | +$22M | 0.09% | 184 |
|
|
2021
Q2 | $3.05M | Buy |
36,518
+17,527
| +92% | +$1.46M | 0.01% | 597 |
|
|
2021
Q1 | $1.43M | Sell |
18,991
-24,346
| -56% | -$1.84M | 0.01% | 839 |
|
|
2020
Q4 | $3.8M | Buy |
43,337
+19,677
| +83% | +$1.73M | 0.01% | 579 |
|
|
2020
Q3 | $1.8M | Buy |
23,660
+3,082
| +15% | +$234K | 0.01% | 699 |
|
|
2020
Q2 | $2.54M | Buy |
20,578
+19,596
| +1,996% | +$2.42M | 0.01% | 673 |
|
|
2020
Q1 | $83K | Buy |
+982
| New | +$83K | ﹤0.01% | 1387 |
|